吉西他滨联合吉非替尼治疗不可切除或转移性胰腺癌患者：希腊合作肿瘤学组的一项II期研究及生物标志物评估
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
作者信息
Fountzilas George, Bobos Mattheos, Kalogera-Fountzila Anna, Xiros Nikolaos, Murray Samuel, Linardou Helena, Karayannopoulou Georgia, Koutras Angelos K, Bafaloukos Dimitrios, Samantas Epaminondas, Christodoulou Christos, Economopoulos Theofanis, Kalogeras Konstantine T, Kosmidis Paris
机构信息
Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
出版信息
Cancer Invest. 2008 Oct;26(8):784-93. doi: 10.1080/07357900801918611.
The combination of gemcitabine and gefitinib was evaluated in advanced pancreatic cancer. Totally, 53 patients were treated with a 7 week cycle of gemcitabine (1,000 mg/m(2) given weekly) followed by six 4 week cycles of gemcitabine given on days 1, 8 and 15. Gefitinib 250 mg was administered daily. Responses were seen in 6, and stabilization of the disease in 12 patients. The main toxicity was myelotoxicity (92%). The 6-month progression-free survival (PFS) was 30%. Median PFS was 4.1 months and median survival 7.3 months with a 1 year survival rate of 27%. The above combination demonstrated promising activity in advanced pancreatic cancer.
对吉西他滨与吉非替尼联合用药治疗晚期胰腺癌进行了评估。共有53例患者接受治疗，采用为期7周的吉西他滨治疗周期（每周给予1000mg/m²），随后是六个为期4周的吉西他滨治疗周期，分别在第1、8和15天给药。每日给予吉非替尼250mg。6例患者出现缓解，12例患者病情稳定。主要毒性为骨髓毒性（92%）。6个月无进展生存期（PFS）为30%。中位无进展生存期为4.1个月，中位生存期为7.3个月，1年生存率为27%。上述联合用药方案在晚期胰腺癌中显示出有前景的活性。
Zotero 插件